ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 016,65
0,00%
Dow Jones
38 085,80
-0,98%
DAX
17 923,79
0,00%
Brent Oil
88,235
0,10%
Bitcoin
64 410,27
-0,12%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Actualités

AIM AIM ImmunoTech Inc

0,4065
-0,0235 (-5,47%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AIM ImmunoTech Inc AIM AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0235 -5,47% 0,4065 00:36:42
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,43 0,375 0,4388 0,4065 0,43
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/4/202414:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/4/202417:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/4/202414:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/4/202413:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/3/202413:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/3/202414:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/3/202414:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/3/202413:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/3/202414:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/3/202413:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/3/202414:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/2/202414:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
21/2/202416:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
20/2/202422:31EDGAR2Form 8-K - Current report
14/2/202414:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
09/2/202421:47EDGAR2Form 8-K - Current report
08/2/202414:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
25/1/202423:00EDGAR2Form 8-K - Current report
24/1/202415:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/1/202414:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/1/202419:42EDGAR2Form 8-K - Current report
10/1/202414:45EDGAR2Form 8-K - Current report
10/1/202414:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/1/202419:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/1/202422:24EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202422:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
03/1/202422:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202314:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/12/202314:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202322:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202322:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202318:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
20/11/202323:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
20/11/202315:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
20/11/202313:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/11/202315:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
15/11/202313:30EDGAR2Form 8-K - Current report
15/11/202313:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
14/11/202316:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
09/11/202314:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
08/11/202322:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/11/202314:45EDGAR2Form 8-K - Current report
08/11/202314:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
07/11/202312:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/11/202315:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..
06/11/202315:09EDGAR2Form DEFC14A - Definitive proxy statement, contested..

Dernières Valeurs Consultées

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés